Company ProfilePremium

Coreana Cosmetics Co., Ltd.

Company Profile Analysis

Ticker: 027050.KQ주식회사 코리아나화장품

ESOMAR 23 Corporate BadgeISO Certifications Badge
Coreana Cosmetics Co., Ltd. - Company showcase

Year Founded & Workforce

1988

167 Employees

Coreana Cosmetics Co., Ltd. logo

Coreana Cosmetics Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Coreana Cosmetics Co., Ltd. Overview

Coreana Cosmetics is a mid-sized, vertically integrated Korean beauty manufacturer founded in 1988. It formulates and produces skincare, colour cosmetics, hair and body products at its own plant and laboratory in Cheonan. It sells them mainly through a door-to-door "beauty counsellor" direct-sales network, which it pioneered at scale in the early 1990s, and supplements this with specialty-store brands, an esthetic salon chain (Cellenique), online channels and exports. A wholly owned subsidiary in Tianjin, China, adds manufacturing and ODM/OEM capacity. Coreana was Korea's third-largest cosmetics company in the 1990s, with revenue above KRW 300 bn at its 2000–2001 peak. It is now a sub-KRW 100 bn niche player: FY2025 revenue was KRW 73.7 bn, with an operating loss of KRW 4.4 bn. The company is debt-light and asset-backed (P/B about 0.6x) but structurally challenged. Its strategic bets are the Ample:N derma brand, online direct sales and global K-beauty distribution.


What the company does. Coreana develops, manufactures and sells cosmetics: basic (skincare), colour, hair and body products. It also runs a skin-care salon chain and earns real-estate rental income. Morningstar classifies the business as household and personal products. Coreana's own product taxonomy groups the range into "solutions" lines: Power Cell, Collagen, Sun, Moisture, Homme, Wrinkle, White, Pore and Clean, plus make-up. The filed objects clause is far broader than current operations. It covers cosmetics and quasi-drug manufacturing, import/export, beauty academies, real-estate leasing, museum operation, health functional foods, e-commerce and skin-care devices. The company actively uses only a fraction of these.

Company's own description (paraphrased from filings and corporate profile). Management describes Coreana as a company that has pursued "Only the Best" quality for over three decades under the slogan "Art through Nature". Its stated management principles are customer satisfaction, ethical (정도) management and a "luxury-goods" (명품주의) product philosophy. Its own facilities handle research, production and distribution. The FY2025 business report ascribes the year's losses to three factors:

  • input-cost inflation that has become structurally embedded;

  • a prolonged slowdown in Greater China, together with weaker K-beauty competitiveness, which stalled exports;

  • a contracting person-to-person (방문판매) sales market.

Revenue model. Revenue is almost entirely product sales, with small service and rental components:

Product mix (latest). In Q2 2026, basic (skincare) cosmetics made up about 72% of revenue, "other cosmetics" (hair, body, other) about 22%, colour cosmetics about 5% and other sales about 1% (DART business segment data via Butler).

Value-chain position. Coreana is an integrated brand owner. It controls formulation (Song-pa Institute of Technology), manufacturing (Cheonan plants 1 and 2; Tianjin plant), brand marketing and a large part of distribution (direct sales, own salons, own online malls). This contrasts with asset-light "indie" K-beauty brands, which outsource production to ODMs such as Cosmax, Kolmar Korea or Cosmecca. Coreana also acts as an ODM/OEM supplier in China through its Tianjin subsidiary.

Customer types and end-markets. The core domestic customer is a middle-aged and older Korean woman, reached through relationship-based direct selling. That demographic is ageing, and its channel is shrinking. Ample:N, with K-pop brand ambassadors The Boyz's Hyunjae (2023–24) and Seventeen's Dokyeom (2025–26), targets 20–30-year-olds through Olive Young and Chicor. B2B customers include Chinese brand owners and distributors served from Tianjin, plus overseas distributors (Thailand Watsons, Philippines Shopee, Tmall Global flagship).

Independent characterisation. Coreana is a legacy direct-sales cosmetics house whose franchise has eroded for two decades. Revenue fell from roughly KRW 300–400 bn (2000–2003) to KRW 73.7 bn (FY2025). The company has kept its manufacturing and R&D base intact rather than becoming asset-light. That base, a debt-free balance sheet and a large treasury-share holding explain why the stock trades at about 0.6x book. The operating question is whether younger brands (Ample:N) and export or online channels can grow faster than the legacy direct-sales franchise declines. Through H1 2026, they have not.

Strategy

Stated strategy (themes from management communications).

2019 "Next 100 Years": team-innovation management, leading technology, customer-happiness management, with emphasis on R&D and global business.

30th anniversary (Nov 2018): "PASS 30 AHEAD 100", with brand-value innovation across R&D, marketing and production.

2023: "Serve the customer" (고객을 모시자), built on three principles: direct-sales innovation, stronger marketing, customer-centricity. The CEO also cited expansion of the bio business.

FY2025 disclosure (Feb 2026): management frames the challenge as structurally higher input costs, Greater China weakness and a shrinking person-to-person channel. No explicit turnaround programme with quantified targets was found.

Strategic initiatives, last 24 months (Oct 2024 – Oct 2026)

Medium-term targets and guidance. None published. Coreana does not issue earnings guidance, and no investor-day material was found. The last quantified public target found was 2012's KRW 120 bn revenue goal, which was not achieved.

ESG and sustainability commitments. CCM consumer-centred certification (8th renewal, 2022) and long-running International Vaccine Institute donations (13 consecutive years by Dec 2024). No emissions targets were published.

Products & Services

Coreana does not publish list prices or volumes in its filings, so pricing is "not publicly disclosed" unless stated. Launch years come from company history where available.

Core skincare brands (Basic cosmetics, ~72% of revenue)

BrandDescription and positioningKey lines / flagship productsTarget customerLaunch / latestChannel
LAVIDA (라비다)Flagship premium anti-ageing brand of the direct-sales channel. Originally a functional brand of subsidiary Artpia. Sold in export markets as "Coreana Premium".Power Cell Essence S (built on the in-house Signalosome™ ingredient, developed from miRNA research on wrinkles, whitening and moisture); Moisture Solution; Power Cell line; Sun Solution (packaging award). 12 consecutive "Brand of the Year" awards (2024); Moisture Solution and Power Cell shortlisted at Pentawards (Oct 2024).Women 40+; direct-sales clienteleRelaunched 2012 (model Kim Ha-neul); ongoingDirect sales, Lavida Shop online mall (Dec 2023), Lavida mall, exports
Ample:N (앰플엔)Derma-cosmetic, "low-irritation, high-function" ampoule brand; the company's main growth and youth brandPeptide Shot, Ceramide Shot and Hyaluronic Shot ampoules; Blemishot Ampoule (Mar 2025) and Blemishot Cream; Hypershot range (2026): Peptide, Ceramide and Cica PDRN ampoules; "Horangi Jakdo" and "Chaekgado" limited K-editions (traditional Korean painting packaging)20–30-year-olds; inbound tourists; overseas consumersLaunched 12 Apr 2017; Hypershot 2026Olive Young (online 2021; offline incl. Olive Young N Seongsu 2024), Chicor, Naver brand store, Watsons TH, Shopee PH, Amazon; pop-ups in Gangnam (May 2025) and Seongsu (2026), LA pop-ups planned
Orthia (오르시아 / Coreana Orthia)Collagen anti-ageing line; ampoules became a China best-seller in 2015 (subsidiary Biocos sales expected +500%)Perfect Collagen 24K Rose Gold Essence Toner Pad; 24K Rose Gold Essence White Tone-Up Cream SPF50+ PA++++; Perfect Collagen 28 Days Intensive Ampoule Cream; 28 Days Ampoule Sun Cream; Perfect Collagen Foaming Cleanser; 24K Rose Gold MagicMass-premium; China and SEA exportc. 2014–15 peak; ongoingExport, cross-border e-commerce, Korean online
SENITE (세니떼)Started as a fragrance and body brand; now also basic skincare. Main brand for the specialty-store (시판) channel and the name of the "Senite Beauty Shop" franchise network.Senite Prestige skincareMass-premium2010 (model Seo Woo); ongoingSenite Beauty Shops (200 contracted outlets by Nov 2013), specialty stores
PREANGE (프리엔제)Originally a hypermarket brand; repositioned as a cosmeceutical brandCosmeceutical skincareIngredient-led consumersShinsegae Chicor online entry Jun 2021Chicor, online
RODIN (로댕)Originally a men's specialty-store brand; now a functional cosmetics brandFunctional skincareMen / functionalOngoingSpecialty stores, online
GAON (가온)Vegan cosmetics brandVegan skincareClean / vegan consumersOngoingOnline, retail
Korean Therapy Gayeonhwa (한방가연 / 가연화)Herbal (hanbang) cosmeticsHerbal skincareOlder consumers; traditional-medicine positioningOngoingDirect sales, specialty
Bichigain (비취가인)Began in direct sales ("Powdery Spa"); now a specialty-store hanbang brandHerbal skincareSpecialty-store customersOngoingSpecialty stores
ZAIN (자인)Premium herbal brand; cited as popular in China (2015)Premium herbal skincarePremium / China2000s; ongoingDirect sales, export
Fermented Mung Bean (발효녹두)Natural-ingredient line descended from the "Mung Bean" franchiseMung-bean based skincareNatural-ingredient seekers2000s; ongoingVarious
Winage (위네이지)Mainstream legacy line, first a sub-line of Astra21; widely known among older consumersPremium Rose Vital line (Korea Package Design award 2023)40+2000s; Rose Vital 2023Direct sales
INSLAB, ARTSCIEN, AGANOORI, SEDUIREAdditional active brands listed in the S&P Global business descriptionDetails not publicly disclosedVarious——
Biocos (비오코스)Brand/entity behind Orthia's China surge (2015)Orthia ampoulesChina2010sExport
Coreana (corporate brand)Masterbrand: legacy lines and new mass itemsCoreana Aloe Soothing Gel (Jeju aloe, low-temperature extraction, with hyaluronic acid, centella and panthenol; launch dated c. 2025 from press archive); Coreana Black Diamond; Coreana Bio (trademarks)BroadAloe gel c. 2025Coreanamall, online

Colour cosmetics (~5% of revenue)

BrandDescriptionNotes
Ten Seconds (텐세컨즈)Coreana's make-up lineSpecific SKUs not publicly disclosed
Merbe (메르베), legacy1994 specialty-store brand that succeeded ArtpiaProduced the hit "Merbe Face Powder"; status not confirmed

Hair, body and other cosmetics (~22% of revenue)

These categories include shampoo, rinse and body products, a heritage dating to the company's first own product, the 1989 Bubble Bubble shampoo. Senite originally carried fragrance and body ranges. The company also manufactured toothpaste and mouthwash (2016 statement on CMIT/MIT). Line-by-line catalogue data for hair and body SKUs is not publicly disclosed.

Services, devices and non-cosmetic offerings

OfferingDescriptionStatus
Cellenique (세레니끄)Premium esthetic skin-care salon chain using and retailing its own product line. 15 branches as of May 2026: Gongdeok, Dangsan, Daechi, Mokdong, Banpo Xi, Bangbae-Sadang, Yeouido, Hannam-Oksu, Wangsimni, Eunpyeong, Jamsil, Gwacheon, Sanbon, Wirye, Pyeongchon. Two closed in 2025: Yongsan-Namyeong and Jamsil World Mark.Operating; awards include the "First Brand" esthetic category, 9 consecutive years (Jan 2025)
Everview ProPremium home-care beauty device with seven functions, unveiled under Ample:N (2026)New; pricing not disclosed
Wellbeing Life (웰빙라이프)Health functional food brandSmall; status not disclosed
Coreana Beauty Centre / Beauty InstituteBeauty education and counselling centresLifelong-education institute since closed
Real-estate rentalLeasing of owned propertyOngoing

Discontinued or heritage brands (context for brand equity)

Ensia (orange line, a major hit), Astra21 (sports cosmetics under a Samsung C&T licence, modelled by Jung Woo-sung in 2000), Artpia (1990–95 specialty-store brand), Crezh (1995, withdrawn after a trademark dispute with Courrèges), Bio Defense (its replacement), Ceredie, Cerebio. The legacy "Mud Pack" was a Chosun Ilbo hit product in 1993 and 1998. Yves Rocher, distributed 1989 onward (ADN, Florilia, Sérélis, Trimaran), was the founding licence.

Financial Narrative

Income statement (consolidated)

Notes on sources and precision

  • Revenue, operating income and net income come from DART via Butler/Chickstock.

  • FY2025 exact figures from the 10 Feb 2026 30%-change disclosure: revenue KRW 73,677,182,497; net loss KRW 7,746,558,039. Operating loss was KRW 4.394 bn (Namu Wiki/DigitalToday).

  • FY2024 exact: revenue KRW 82,451,674,673; net income KRW 783,926,037. FY2024 operating income back-solves to about KRW 0.44 bn from the reported −1,096.8% change.

  • FY2022 net income appears as KRW 1.5 bn (Butler) and KRW 1.6 bn (Dealsite, citing the Feb 2023 disclosure), a minor rounding or attribution discrepancy.

  • FY2025 EBITDA of about KRW −1.5 bn is TradingView's computed figure (EBITDA margin −2.55%). Its period basis is not stated, so treat it as approximate. It implies D&A of roughly KRW 2.5–3.0 bn a year.

  • Gross profit: Simply Wall St (S&P Global data) shows TTM to Sep 2025 revenue KRW 76.5 bn and gross profit KRW 27.1 bn (35.4% margin). TTM to Jun 2026 shows KRW 71.7 bn and KRW 24.2 bn (33.7%).

  • TTM EPS is −KRW 225 (Chickstock, H1 2026 TTM) versus −KRW 278.45 (Simply Wall St, TTM Jun 2026). The gap likely reflects differences in the share base (treasury shares) and minority-interest treatment.

  • Dividends: no dividend yield is shown for the current period (Butler: "–").

Revenue CAGR. FY2021–FY2025: −4.1% a year (KRW 87.1 bn to 73.7 bn). FY2016 to FY2025, using KRW 117.7 bn for FY2016 as reported on the Incruit company profile: about −5.1% a year.

Parent-company (separate) results

Sources: Incruit/NICE; Namu Wiki (FY2025 separate operating loss KRW 4.63 bn, net loss KRW 6.75 bn).

Balance sheet

Sources and notes

  • FY2025 consolidated total assets KRW 108.35 bn and liabilities KRW 22.26 bn are from Namu Wiki's reproduction of the FY2025 business report; equity is derived.

  • End-2024 current assets and current liabilities are from iNews24 (Jul 2025), citing DART.

Debt profile (known data points)

  • Short-term borrowings were KRW 4.75 bn at 31 Mar 2025, maturing Mar 2026. Management stated no other loans. Debt ratio was 24.32% and net debt ratio 0.72% at that date (iNews24).

  • The July 2025 treasury-share sale (KRW 5.57 bn) was explicitly to repay this loan and fund operations.

  • By Jun 2026, Simply Wall St shows debt/equity of 1.2%. On roughly KRW 84 bn of equity, that implies borrowings of about KRW 1 bn, so net debt is effectively nil or negative.

  • Total equity at Jun 2026 is about KRW 84 bn, consistent with BPS of KRW 2,103 and P/B of 0.59x at a KRW 49.8 bn market cap.

Cash flow

Sources and notes

  • FY2025 operating cash flow of −KRW 1.6 bn is from Chickstock's financial-intelligence flag (operating loss plus negative operating cash flow).

  • The FY2024 buyback value is the board-approved amount: an acquisition decision of about KRW 0.8 bn, announced roughly December 2024 (Edaily).

  • Earlier buyback decisions: KRW 2.84 bn (440,000 shares, Jun–Jul 2017); KRW 0.29 bn (100,000 shares, Jun 2022); trust contract of KRW 3 bn extended to Jun 2014.

  • The FY2025 disposal was 2,000,000 shares at KRW 2,784 (25 Jul 2025).

Ratios

Notes

  • FY2025 ROE, ROA and asset turnover are computed on year-end balances; average balances were not available.

  • TTM ROE to Jun 2026 is −10.7% (Chickstock) or −11.3% (Chickstock financials page, different cut-off).

  • Interest coverage is negative in FY2025 (operating loss).

  • Debt/equity is 1.2% at Jun 2026 (Simply Wall St).

Commentary — trends, inflections and drivers

Revenue: structural decline with China volatility layered on top. Coreana's revenue has been on a long downward path since its 2000–2003 peak, when annual sales approached KRW 300–400 bn. Press accounts attribute the decline to the 2003 credit-card crisis, the rise of single-brand road shops (Missha, The Face Shop and similar) and new direct-sales entrants that undercut the company's core channel. Within FY2021–FY2025, the pattern alternates:

  • FY2022 contraction (−7.7%), driven by China's Covid lockdowns hitting the offline-heavy Tianjin subsidiary;

  • FY2023 recovery (+7.0%), with Q1 2023 described as export-driven;

  • renewed declines in FY2024 (−4.1%) and FY2025 (−10.6%).

The FY2025 decline was sharpest in the implied subsidiary contribution, down about 43%, while the parent fell a more modest 2.9%.

Profitability: margins have compressed to below break-even. Operating margin fell from 3.9% (FY2021) to around 1% (FY2022–FY2023), 0.5% (FY2024) and −6.0% (FY2025). Management's FY2025 explanation names a structural rise in raw-material and packaging costs and the loss of operating leverage on a shrinking top line. Gross margin of about 34–35% (TTM) is low for an own-brand cosmetics company; Korean beauty brand owners typically operate well above 50%. The H1 2026 operating loss of about KRW 1.6 bn is a large improvement on FY2025's run-rate. However, Q2 2026 (−KRW 1.1 bn) deteriorated from Q1 2026 (−KRW 0.5 bn).

Below-the-line items. FY2025 net loss (−KRW 7.7 bn) exceeded operating loss (−KRW 4.4 bn) by about KRW 3.3 bn. That points to non-operating charges: impairments, valuation losses on financial or equity-method assets, or tax effects. Q1 2026's small net profit (KRW 0.2 bn) despite an operating loss suggests non-operating income (interest, rental, FX) in that quarter.

Balance sheet: conservative and asset-heavy. With about KRW 108 bn of assets, only about KRW 22 bn of liabilities, minimal borrowings and owned real estate (Cheonan HQ/plant, Gwanggyo building), Coreana's solvency risk is low. The company has twice used asset monetisation to stay debt-free: the Seocho building sale (KRW 32 bn, 2011–12) and the 2025 treasury-share sale. The main financial risk is not leverage but cash burn. Negative operating cash flow (FY2025) combined with continued losses will gradually erode equity and liquidity if the business does not return to break-even.

Capital allocation. For over a decade Coreana bought back stock periodically (2013 trust, 2017, 2022, 2024), accumulating about a quarter of its issued shares in treasury. The July 2025 reversal, which sold 5% of the company for a modest short-term loan, was criticised as unnecessary given end-2024 current assets of KRW 26.2 bn against current liabilities of KRW 13.6 bn. It signals that management is prioritising liquidity over per-share value. No dividends appear to have been paid recently.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipOwnershipFunctionSource

Coreana Cosmetics Co., Ltd.

Parent (listed)

—

Brand ownership, Cheonan manufacturing, R&D, domestic sales, exports

DART

Coreana Tianjin Co., Ltd. (코리아나천진유한공사)

Consolidated subsidiary

100%

China manufacturing, local sales, ODM/OEM

Company; Namu Wiki; Dealsite (2023)

Artpia Co., Ltd. (㈜아트피아)

Consolidated subsidiary

63.21%

Cosmetics brand and sales entity (est. 1997)

Company; Namu Wiki

Coreana Bio Co., Ltd. (코리아나바이오)

Associate (equity method)

20.20%

Bio/ingredient affiliate; also holds 300,000 Coreana shares (0.75%) as a related party

Company; large-shareholding report (Sep 2026)

Segment Revenue

CategoryContentsShare of revenue, Q2 2026 (%)

Basic (skincare) cosmetics

Toners, emulsions, essences, ampoules, creams, sun care, cleansers

72

Other cosmetics

Hair care, body care, fragrance, other

22

Colour cosmetics

Make-up (e.g., Ten Seconds, cushions, powders)

5

Other sales

Services, rental, merchandise

1

Revenue by Segment and Revenue by Segment (%)

MetricFY2023FY2024FY2025

Consolidated revenue (KRW Bn)

86.082.573.7

Parent (separate) revenue (KRW Bn)

70.466.664.7

Implied subsidiaries net of eliminations (KRW Bn)

15.615.99.0

Parent share of consolidated revenue (%)

81.980.787.8

Parent revenue YoY growth (%)

—-5.4-2.9

Implied subsidiaries YoY growth (%)

—1.9-43.4

Revenue by Segment

MetricFY2023FY2024

Likely Tianjin subsidiary revenue (KRW Bn)

18.216.3

Likely Tianjin subsidiary operating profit (KRW Bn)

0.751.75

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

87.180.486.082.573.7

Revenue growth YoY (%)

—-7.77.0-4.1-10.6

Operating income (KRW Bn)

3.40.90.90.4-4.4

EBITDA (KRW Bn)

————-1.5

Net income (KRW Bn)

3.31.51.80.8-7.7

Operating margin (%)

3.91.11.00.5-6.0

Net margin (%)

3.81.92.11.0-10.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricFY2023FY2024FY2025

Separate revenue (KRW Bn)

70.466.664.7

Separate operating income (KRW Bn)

——-4.6

Separate net income (KRW Bn)

1.80.1-6.8

Separate total equity (KRW Bn)

86.286.183.7

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue (KRW Bn)

19.120.516.817.418.618.9

Revenue YoY (%)

——-14.0—-2.4-7.7

Operating income (KRW Bn)

————-0.5-1.1

Net income (KRW Bn)

——-2.6—0.2-1.1

Balance Sheet and Margin Analysis (%)

MetricFY2024FY2025

Total assets (KRW Bn)

—108.3

Total liabilities (KRW Bn)

—22.3

Total equity (KRW Bn)

—86.1

Current assets (KRW Bn)

26.2—

Current liabilities (KRW Bn)

13.6—

Liabilities-to-equity (%)

—25.9

Separate total assets (KRW Bn)

—97.8

Separate total liabilities (KRW Bn)

—14.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY2024FY2025

Operating cash flow (KRW Bn)

—-1.6

Treasury-share purchases (KRW Bn)

0.8—

Treasury-share disposal proceeds (KRW Bn)

—5.6

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025

ROE (%)

—-9.0

ROA (%)

—-7.1

Current ratio (x)

1.93—

Liabilities / equity (%)

—25.9

Asset turnover (x)

—0.68

Revenue by Region and Region Margins & Growth (%)

MetricFY2023FY2024FY2025

Korea-domiciled revenue, parent separate (KRW Bn)

70.466.664.7

China-domiciled revenue proxy, consolidated minus separate (KRW Bn)

15.615.99.0

Korea-domiciled growth (%)

—-5.4-2.9

China proxy growth (%)

—1.9-43.4

China proxy share of consolidated revenue (%)

18.119.312.2

Valuation Snapshot

MetricValueDate / source

Last close

KRW 1,240 (+2.06%)

19 Oct 2026, Chickstock (KOSCOM)

Market capitalisation

KRW 49.8 bn

19 Oct 2026

52-week high / low

KRW 3,055 (30 Oct 2025) / KRW 1,150 (30 Jul 2026)

Chickstock

Price on 10 Feb 2026 (FY2025 results)

KRW 2,260

DigitalToday

Treasury-share disposal price

KRW 2,784

25 Jul 2025

Daily trading value

~KRW 16.2 m (19 Oct 2026); illiquid

Chickstock

Beta (1Y)

0.19

TradingView

1-year price change

About −52% (TradingView snapshot); about −59% from the 52-week high to the current price

TradingView; Chickstock

Share Price

MetricJul 2025Feb 2026Sep 2026Oct 2026

Share price (KRW)

2,7842,2601,3271,240

Valuation Multiples

MultipleCoreanaKorean cosmetics sector medianBasis

P/E (TTM)

Negative (−5.53x)

12.71x (35 profitable names, 8 Oct 2026)

Chickstock, H1 2026 TTM

P/B

0.59x

1.25x to 1.29x (55–57 names)

Chickstock

P/S (EV/Sales proxy)

0.69x

0.99x to 1.11x

Chickstock

EV/EBITDA

Not meaningful (negative EBITDA)

—

TradingView EBITDA ~−KRW 1.5 bn

Profitability-matched peers (10 companies)

—

Typically ~13.0x P/E

Chickstock

Capital Markets

ItemDetail

Dividend policy

No published policy; no current dividend yield (Butler, Oct 2026).

Buyback history

Trust contract of KRW 3 bn extended to Jun 2014; 440,000 shares (KRW 2.84 bn) decided Jun 2017; 100,000 shares (KRW 0.29 bn) decided Jun 2022; KRW 0.8 bn decided c. Dec 2024

Treasury disposals

2,000,000 shares (KRW 5.57 bn), 25 Jul 2025, the first in company history

Current treasury holding

19.50% (~7.8 m shares)

Current buyback authorisation

None active found

Moody's / S&P / Fitch

Not rated

Domestic corporate credit evaluation

Rated "양호" (sound) as of Mar 2026 on the Catch/NICE profile; this is a commercial credit evaluation, not a bond rating

Bonds outstanding

None identified

Debt maturity profile

Short-term borrowings of KRW 4.75 bn were due Mar 2026, with repayment funded by the Jul 2025 treasury sale. Debt/equity was 1.2% at Jun 2026, so no material maturities are outstanding.

Analyst Conclusions

Management guidance. None issued. Management's only forward-looking framing in filings is diagnostic: cost inflation, China and the decline of the person-to-person channel are structural. Brand-level communications point to global expansion of Ample:N, including overseas pop-ups.

Consensus growth expectations. None; the stock is uncovered. Using the run-rate method, H1 2026 revenue of KRW 37.5 bn annualises to about KRW 75 bn, roughly flat to slightly up on FY2025's KRW 73.7 bn. The H1 operating loss of about KRW 1.6 bn annualises to about −KRW 3 bn, an improvement on −KRW 4.4 bn but still a loss. This is an analytical extrapolation, not a forecast from any third party.

Bull case

  1. Deep asset discount with a capital-return lever. At 0.59x book, the market prices Coreana well below net assets, which include owned plants, a Gwanggyo building and an R&D campus. A 19.5% treasury holding could be cancelled to raise BPS. Korea's value-up policy push and the ownership-reporting transition to Yu Hak-soo (Sep 2026) create a plausible catalyst window.

  2. Loss narrowing is visible. The operating loss improved from −KRW 4.4 bn (FY2025) to about −KRW 1.6 bn (H1 2026), and Q1 2026 posted a net profit. Further cost actions (salon rationalisation, Tianjin cost control, which raised FY2024 subsidiary operating profit by KRW 1.0 bn) could restore break-even on flat revenue.

  3. Ample:N rides the strongest K-beauty vector. Skincare exports are growing 25% and US exports 41.5% (H1 2026). Ample:N already has Olive Young flagship placement, K-pop ambassadors, barrier, peptide and PDRN products and a device extension. Modest export traction would be material on a KRW 74 bn revenue base.

Bear case

  1. Structural decline outruns new initiatives. Revenue fell in three of the last four years. H1 2026 continued to decline (Q2 −7.7%) despite record national exports, which shows Coreana is losing share. The person-to-person channel driving Lavida is contracting by management's own admission.

  2. China leg is breaking. The implied subsidiary contribution fell 43% in FY2025. The KAIXIN contract term ends in 2026, and national exports to China are falling. Further Tianjin erosion would remove the group's historically profitable subsidiary.

  3. Capital allocation and governance weigh on value realisation. The 2025 treasury-share sale for a small loan, the low family economic ownership (16.08%) and the absence of dividends, guidance or IR engagement suggest the asset discount may persist. Continued negative operating cash flow could force further asset monetisation on poor terms.

Key catalysts and monitorables (next 12 months)

CatalystTimingWhat to watch
Q3 2026 quarterly reportBy 16 Nov 2026Whether the Q2 operating loss (−KRW 1.1 bn) reverses; China proxy trend
FY2026 results / 30%-change disclosure~Feb 2027Return to operating break-even vs a second loss year
KAIXIN contract renewal or replacement2026–27Disclosure of new China ODM contracts
Treasury-share decision (cancellation or further disposal)Any time; AGM Mar 2027Direction of capital allocation
Ample:N overseas pop-ups (LA) and US e-commerce2026–27Disclosed export growth
Ownership and succession filingsOngoingFurther transfers between Yu Sang-ok and Yu Hak-soo; any change in control
Gross marginQuarterlyRecovery above ~35% needed for sustainable profitability
Operating cash flowSemi-annualSign change to positive

Concluding analyst verdict

Coreana Cosmetics is a heritage Korean beauty franchise in managed decline. It has a fortress-like balance sheet and has so far been unable to participate in the most powerful growth cycle in its industry's history. While Korean cosmetics exports rose 27% to a record USD 7.0 bn in H1 2026, Coreana's consolidated revenue fell year on year in both quarters. Its FY2025 result was a KRW 4.4 bn operating loss on KRW 73.7 bn of revenue. The causes are structural rather than cyclical: the company's core person-to-person sales channel is shrinking, its China subsidiary's contribution nearly halved, and a gross margin of about 34% leaves little room to absorb input-cost inflation.

The bull case is primarily an asset story. At KRW 1,240 the stock trades at 0.59x book and about 0.7x sales. It has negligible debt, owned industrial and office real estate, and a 19.5% treasury block that could be cancelled. Losses narrowed meaningfully in H1 2026, and Ample:N is positioned in the right product trends and retail doors. If management combined cost discipline with treasury-share cancellation or an asset unlock, the discount to book could narrow.

The evidence on capital allocation, however, points the other way. The first-ever treasury-share sale in July 2025 was used to retire a small loan. There is no dividend, guidance or investor engagement, and controlling-family economic ownership is low at 16.08%. Until Coreana demonstrates either operating break-even, positive operating cash flow or a shareholder-aligned use of its treasury stake, the valuation discount is more likely to persist than close.

The overall assessment is a deep-value, low-quality situation with asymmetric dependence on management action. Investors should treat the Q3 2026 report, any KAIXIN successor contract and any treasury-share resolution as the decisive near-term signals. Absent these, the risk of slow book-value erosion through continued losses outweighs the optionality.


APPENDIX — SOURCE KEY

Primary filings (DART/KIND) are referenced through the reproductions listed below; figures were cross-checked where two or more sources were available.

Data gaps to close from DART before use in a board document: FY2021–FY2025 gross profit, EBITDA, EPS and DPS; cash, debt and capex series; R&D expense; auditor; ISIN; board composition and pay; FY2025 non-operating items; KAIXIN contract status; the reason for the Aug–Sep 2026 change in shareholding reporter.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenureBackground / educationAge

Yu Sang-ok (유상옥)

Founder; Chairman, listed as Representative Director & Chairman in public profiles. Current registered-director status should be confirmed in the latest DART report.

Founder 1988; CEO 1988–2008

Joined Dong-A Pharmaceutical in 1959 in its first open-recruitment class; credited with building the Bacchus brand; turned around Rami Cosmetics (CEO from 1977); later chaired Dong-A Glass. Master's in business administration; doctorate from Union University (US) per Money Today profile. Order of Civil Merit (Moran Medal); Order of Cultural Merit for art collecting; 27th "Proud Museum Person" award (May 2024). Author of ten books.

About 93 (born c. 1933; inferred from age 71 in Oct 2004 and 88 in Dec 2020)

Yu Hak-soo (유학수)

President & CEO (Representative Director)

CEO since 1 Jan 2008 (co-CEO with Kim Tae-joon 2008–09); designated successor Dec 2007

Eldest son of the founder. Declared zero-borrowing management (2012); launched Lavida (2012) and Ample:N (2017).

—

Yu Seung-hee (유승희)

Director (관장) of Coreana Museum of Art; major shareholder (2.97%)

Co-director of the museum with the founder

Founder's daughter

—

Other executive officers, CFO and independent directors

——

Consult the FY2025 business report, Part VIII (임원 및 직원).

—

“—” = not publicly disclosed.

Major Shareholders

HolderSharesStake (%)Source / date

Treasury shares (Coreana Cosmetics)

~7,800,000

19.50

Butler (DART-derived), Oct 2026

Yu Hak-soo (CEO; reporting representative)

2,100,0005.25

Large-shareholding report, 15 Sep 2026

Yu Seung-hee (daughter)

1,187,1772.97

Same

Yu Sang-ok (founder)

1,100,6152.75

Same

Coreana Bio (affiliate, 20.20%-owned associate)

300,0000.75

Same

Other related parties (12 persons)

~1,745,635

~4.36

Derived: group total minus named holders

Controlling group total (17 persons incl. Yu Hak-soo)

6,433,427

16.08

Same

Free float (residual)

~25,766,573

~64.4

Derived

Competitive Landscape

Key Competitors

CompetitorArena overlapScale indicatorSource

Amorepacific

Direct sales, prestige skincare, China

Market cap ~KRW 8.6 tn

Simply Wall St (Oct 2026)

LG H&H

Direct sales, prestige herbal skincare (The Whoo), China

Market cap ~KRW 4.2 tn

Simply Wall St

APR

Derma / device-led skincare (Medicube), global online

Market cap ~KRW 12.2 tn

Simply Wall St

Cosmax

ODM incl. China

FY2024 revenue KRW 2,166.1 bn; operating income KRW 175.4 bn; market cap ~KRW 3.4 tn

CNC News (Feb 2025); Simply Wall St

Kolmar Korea

ODM incl. China (Wuxi)

FY2024 revenue KRW 2,452.1 bn; operating income KRW 195.6 bn; Q2 2026 revenue KRW 861.3 bn, operating income KRW 110.3 bn

CNC News; Cosinkorea (Aug 2026)

Cosmecca Korea

ODM incl. China (Cosmecca China)

Q3 2025 revenue KRW 182.4 bn; operating income KRW 27.2 bn; FY2024 operating income KRW 60.4 bn; market cap KRW 820.2 bn (May 2026)

Kukinews; Kyobo Securities

DYD (219550)

Small-cap Korean cosmetics

Market cap ~KRW 47.8 bn

Chickstock (Oct 2026)

Bonne (226340)

Small-cap Korean cosmetics

Market cap ~KRW 46.6 bn

Chickstock

J2K Bio (420570)

Small-cap Korean cosmetics

Market cap ~KRW 50.9 bn

Chickstock

CTK (260930)

Small-cap Korean cosmetics

Market cap ~KRW 43.5 bn

Chickstock

SD Biotechnologies (217480)

Small-cap Korean cosmetics

Market cap ~KRW 54.8 bn

Chickstock

Peer Comparison FY2025

MetricCoreana (FY2025)Kolmar Korea (FY2024)Cosmax (FY2024)Cosmecca Korea (FY2024)

Revenue (KRW Bn)

73.72,452.12,166.1—

Revenue growth (%)

-10.61421.9—

Operating income (KRW Bn)

-4.4195.6175.460.4

Operating margin (%)

-6.08.08.1—

Company Snapshot

$51.9M

Revenue

167

Employees

1988

Founded

Cheonan, South Korea

Headquarters

SWOT Analysis

Strengths

  • Debt-light balance sheet. Total liabilities of KRW 22.3 bn against equity of about KRW 86 bn (FY2025, liabilities/equity 25.9%). Debt/equity was 1.2% at Jun 2026 (Simply Wall St).
  • Asset backing. P/B of 0.59x (19 Oct 2026). BPS of KRW 2,103 is 70% above the KRW 1,240 share price. Real estate includes the Cheonan HQ, plant and R&D campus and the Gwanggyo building.
  • Integrated manufacturing. Two Cheonan plants (1990, 2013) plus a Tianjin plant. This allows own-brand production and third-party ODM/OEM (KAIXIN USD 16.7 m contract, 2021–26).
  • Proprietary R&D. The Song-pa Institute and Future Science Lab developed the Signalosome™ ingredient behind Lavida's best-selling Power Cell Essence S. The company cites 481 IP assets.
  • Brand heritage and certifications. First cosmetics firm certified under CCM (2008), renewed eight times (2022). Lavida has 12 consecutive Brand of the Year awards (2024); Cellenique has 9 consecutive First Brand awards (Jan 2025).
  • Youth brand with retail access. Ample:N is stocked in Olive Young (incl. the N Seongsu flagship, Nov 2024) and Chicor, with K-pop ambassadors (2023–26) and pop-ups (2025–26).

Weaknesses

  • Loss-making. FY2025 operating loss KRW 4.4 bn (−6.0% margin), net loss KRW 7.7 bn. H1 2026 operating loss about KRW 1.6 bn.
  • Persistent top-line decline. Revenue down from KRW 87.1 bn (FY2021) to KRW 73.7 bn (FY2025), −4.1% CAGR. Down three of the last four years.
  • Low gross margin. About 33.7% TTM (Jun 2026) versus about 35.4% TTM (Sep 2025). That is thin for a brand owner and leaves little buffer against input inflation.
  • Negative operating cash flow. −KRW 1.6 bn in FY2025 (Chickstock flag).
  • Shrinking organisation. About 167 employees (2025) versus 395 (2009 profile), which limits capacity for new initiatives.
  • Weak disclosure. No IR presentations, no guidance and no analyst coverage. Investors depend on statutory filings alone.

Opportunities

  • US-led K-beauty export boom. US exports +41.5% in H1 2026. Ample:N has an Amazon storefront and LA pop-up plans.
  • Skincare-led demand. Basic cosmetics exports +25% (H1 2026), and Coreana's mix is 72% skincare.
  • Digitised direct sales. Lavida Shop (Dec 2023) can retain the direct-sales franchise at lower fixed cost.
  • Home-care devices. The Everview Pro launch (2026) taps a category where APR has built a KRW 12 tn market cap.
  • Treasury-share holding. The 19.5% treasury stake (~7.8 m shares) could be cancelled to lift per-share value, in line with Korea's 2024–26 "value-up" policy push. It could also be used for a strategic partner.
  • Unlocking idle assets. There is precedent in the 2011–12 Seocho sale (KRW 32 bn).

Threats

  • China structural decline. The implied subsidiary contribution fell 43% in FY2025; Korean exports to China fell 6.6% in H1 2026.
  • Collapse of the core channel. Management explicitly cites contraction of person-to-person distribution (FY2025).
  • Scale disadvantage versus ODM-backed indie brands. Kolmar Korea's Q2 2026 operating income (KRW 110.3 bn) alone is about 1.5 times Coreana's annual revenue.
  • Input-cost inflation. Management calls it "structurally embedded" (FY2025).
  • Contract run-off. The KAIXIN contract term ends in 2026, with renewal unconfirmed.
  • Governance and minority-shareholder risk. Concentrated family control at 16.08% with low economic ownership. The 2025 treasury-share sale was criticised as shareholder-unfriendly.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
8 Jan 2025Cellenique wins "First Brand" award, esthetic category, 9th consecutive yearService-channel brand equity
14 Mar 2025Seventeen's Dokyeom named Ample:N model; Blemishot Ampoule launchedYouth and global marketing push
26 Mar 2025AGM held at Cheonan; FY2024 business review reports a subsidiary (likely Tianjin) at revenue KRW 16.3 bn and operating profit KRW 1.75 bnGovernance; China cost improvement
31 Mar 2025Debt ratio 24.32%; short-term borrowings KRW 4.75 bn (maturing Mar 2026); net debt ratio 0.72%Balance-sheet baseline
9 Apr 2025Global distribution MOU with BM SmileExport channel
22 May 2025First Ample:N pop-up store (Gangnam)Brand experience
c. mid-2025Coreana Aloe Soothing Gel launched (date approximate from press archive)Mass seasonal SKU
2025Cellenique closes Yongsan-Namyeong and Jamsil World Mark branchesFootprint rationalisation
25 Jul 2025First-ever treasury-share disposal: 2.0 m shares at KRW 2,784 (~KRW 5.57 bn) for loan repayment and working capitalPress criticism over shareholder value; dilutes treasury holding from ~24.5% to 19.5%
H2 2025Ample:N model and campaign activity continues; Olive Young presence maintained—
30 Oct 2025Shares hit 52-week high of KRW 3,055Peak before a 60% drawdown
Nov 2025Q3 2025 results: revenue KRW 16.8 bn (−14% YoY); net loss KRW 2.6 bn (EPS −KRW 79 vs +KRW 9)Loss deepening
Nov 2025Simply Wall St flags "earnings declined 12% a year over 5 years" as a major riskData-provider risk flag
10 Feb 2026FY2025 results disclosure (30%+ P&L change): revenue KRW 73.68 bn (−10.6%), operating loss KRW 4.39 bn, net loss KRW 7.75 bn; causes cited are input costs, Greater China slump, weaker K-beauty competitiveness, shrinking person-to-person salesSwing to loss; shares at KRW 2,260
11 Feb 2026AGM convened for 26 Mar 2026—
c. Mar 2026Ample:N Seongsu pop-up (about one month): K-edition packaging, Hypershot ampoules, Everview Pro home-care device; LA pop-up plannedTourist and global push; device entry
26 Mar 2026AGM at CheonanGovernance
15 May 2026Q1 2026 report: revenue KRW 18.6 bn (−2.4%), operating loss KRW 0.5 bn, net profit KRW 0.2 bn. Amended FY2025 business report filed the same day.Loss narrows sharply
May 2026Cellenique operating 15 branchesService footprint
1–3 Jul 2026Industry: in-cosmetics Korea 2026 highlights barrier care, slow ageing and exosomesProduct-trend alignment for Ample:N
Jul 2026Industry: Korean cosmetics exports hit an H1 record of USD 7.0 bn (+27.3%); China −6.6%Macro tailwind, but not in Coreana's China segment
9 Jul 2026Large-shareholding report filedOwnership reporting
30 Jul 2026Shares hit 52-week low of KRW 1,150Trough
14 Aug 2026H1 2026 report: Q2 revenue KRW 18.9 bn (−7.7%), operating loss KRW 1.1 bn, net loss KRW 1.1 bnQ2 setback after Q1 improvement
18 Aug 2026Large-shareholding report filed by Yu Sang-okOwnership-reporting transition
4 Sep 2026Large-shareholding reports by Yu Sang-ok and Yu Hak-soo; group at 16.08% (15 related persons)Reporting representative becomes Yu Hak-soo
11/15 Sep 2026Related party Yu Gyeong-su buys 1,000 shares at KRW 1,327; group remains 16.08% with 16 related personsMinor insider buying
15 Sep 2026Market cap KRW 52.9 bn; TTM P/E −5.57x; P/B 0.63xValuation reference
1 Oct 2026Amended H1 2026 report filed–
19 Oct 2026Shares close at KRW 1,240 (+2.1%); market cap KRW 49.8 bn; P/B 0.59xCurrent valuation
By 16 Nov 2026 (upcoming)Q3 2026 report statutory deadlineNext catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment (FY2023–FY2025): Consolidated revenue fell from KRW 86,000 Mn in FY2023 to KRW 73,700 Mn in FY2025.
Coreana Cosmetics Co., Ltd. — Revenue by Segment (FY2023–FY2025)
Series (KRW Mn)FY2023FY2024FY2025
Consolidated revenue86,00082,50073,700
Parent (separate) revenue70,40066,60064,700
Implied subsidiaries net of eliminations15,60015,9009,000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.